Improvements in our understanding of the human genome, technological tools like artificial intelligence, and global ...

Considering that PD-1/L1 are some of the most lucrative drug treatments across the industry, this could be a major coup for any mRNA developer that manages to successfully co-develop such a treatment.

They could also offer a more potent option to conventional flu shots, according to mRNA vaccine developers. Current flu vaccines generally offer only around 40% to 60% protective efficacy ...

Soluna Holdings, Inc. ("Soluna" or the "Company"), , a developer of green data centers for intensive computing applications including Bitcoin mining and AI, announced today that it has signed the ...

Avidity's delpacibart etedesiran (del-desiran) was granted orphan drug status in Japan as a treatment for myotonic dystrophy ...

CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to ...

The global vaccine CDMO market is set to witness a growth rate of 8% in the next 5 years. Increasing demand for vaccines, ...

Alzheon Inc.’s oral treatment for people in the early stages of Alzheimer’s disease missed its phase III primary endpoint, adding yet another therapy to a long list by many developers that can’t beat ...

The FDA is phasing out animal testing for monoclonal antibody therapies, embracing AI and human-based models. Read more here.

In the default model, the graph representing each individual enhancer can be arbitrarily complicated. To show how the ABC Score formula can arise from the default model, we need to impose the further ...